These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20452456)

  • 21. [ITAP - 6-month results of a prospective, randomised phase 3 study for evaluation of the combination therapy of PDT and intravitreal triamcinolone in exudative AMD].
    Gamulescu MA; Schubert K; Thormann S; Attaran M; Dueck N; Wiechens B; Spital G; Stroux A; Wachtlin J
    Klin Monbl Augenheilkd; 2009 Jan; 226(1):60-5. PubMed ID: 19173165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical results of intravitreal administration of tissue-type plasminogen activator (tPA) and gas for removal of subretinal hemorrhage in senile macular degeneration].
    Framme C; Toukhy HE; Sachs HG; Spiegel D; Roider J; Gabel VP; Lohmann CP
    Klin Monbl Augenheilkd; 2000 Jan; 216(1):33-9. PubMed ID: 10702940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical challenges for developing long acting intravitreal medicines.
    Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
    Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic approaches to age-related macular degeneration in the future.
    Do DV
    Ophthalmology; 2009 Oct; 116(10 Suppl):S24-6. PubMed ID: 19800536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit.
    Li H; Lei N; Zhang M; Li Y; Xiao H; Hao X
    Exp Eye Res; 2012 Apr; 97(1):154-9. PubMed ID: 21933673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials.
    Liu M; Regillo CD
    Curr Opin Ophthalmol; 2004 Jun; 15(3):221-6. PubMed ID: 15118509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging biological therapies for the treatment of age-related macular degeneration.
    Asahi MG; Avaylon J; Wallsh J; Gallemore RP
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):193-207. PubMed ID: 34030572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related macular degeneration and the other double helix. The Cogan Lecture.
    Ambati J
    Invest Ophthalmol Vis Sci; 2011 Apr; 52(5):2165-9. PubMed ID: 21471430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CCR3: Shedding new light on a dark problem?
    Mason AB; Hoh J
    J Mol Cell Biol; 2009 Oct; 1(1):17-9. PubMed ID: 19684049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanodiagnostics and Nanotherapeutics for age-related macular degeneration.
    Sarkar A; Dyawanapelly S
    J Control Release; 2021 Jan; 329():1262-1282. PubMed ID: 33129920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neovascular age-related macular degeneration: roundtable.
    Singerman LJ; Brucker AJ; Jampol LM; Lim JI; Rosenfeld P; Schachat AP; Spaide RF
    Retina; 2005; 25(7 Suppl):S1-S22. PubMed ID: 16208185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adapted and standardised patient management in the treatment of neovascular AMD in the outpatient setting of a university eye hospital].
    Framme C; Wolf-Schnurrbusch UE; Lobsiger H; Bayer S; Wolf S
    Klin Monbl Augenheilkd; 2012 Aug; 229(8):812-21. PubMed ID: 22615063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel quadraport needle with improved intravitreal drug dispersion.
    Asami T; Wong SC; Mitchell PC; Tokunaga CC; Chen YH; Dang L; Giblin FJ; Trese MT
    Retina; 2012 Jun; 32(6):1222-5. PubMed ID: 22596098
    [No Abstract]   [Full Text] [Related]  

  • 34. Proteomics of vitreous in neovascular age-related macular degeneration.
    Nobl M; Reich M; Dacheva I; Siwy J; Mullen W; Schanstra JP; Choi CY; Kopitz J; Kretz FTA; Auffarth GU; Koch F; Koss MJ
    Exp Eye Res; 2016 May; 146():107-117. PubMed ID: 26769219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steerable intravitreal inserts for drug delivery: in vitro and ex vivo mobility experiments.
    Bergeles C; Kummer MP; Kratochvil BE; Framme C; Nelson BJ
    Med Image Comput Comput Assist Interv; 2011; 14(Pt 1):33-40. PubMed ID: 22003597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat(®), for age-related macular degeneration.
    Binley K; Widdowson PS; Kelleher M; de Belin J; Loader J; Ferrige G; Carlucci M; Esapa M; Chipchase D; Angell-Manning D; Ellis S; Mitrophanous K; Miskin J; Bantseev V; Nork TM; Miller P; Naylor S
    Hum Gene Ther; 2012 Sep; 23(9):980-91. PubMed ID: 22716662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal injections: a most recent evidence for best practice.
    Grzybowski A; Ascaso FJ
    Clin Exp Ophthalmol; 2013 Nov; 41(8):816-7. PubMed ID: 23844649
    [No Abstract]   [Full Text] [Related]  

  • 38. Intravitreal injections: a most recent evidence for best practice--response.
    Fagan XJ; Al-Qureshi S
    Clin Exp Ophthalmol; 2013 Nov; 41(8):817-8. PubMed ID: 23844624
    [No Abstract]   [Full Text] [Related]  

  • 39. Intravitreal injection technique and monitoring: updated guidelines of an expert panel.
    Avery RL; Bakri SJ; Blumenkranz MS; Brucker AJ; Cunningham ET; DʼAmico DJ; Dugel PU; Flynn HW; Freund KB; Haller JA; Jumper JM; Liebmann JM; McCannel CA; Mieler WF; Ta CN; Williams GA
    Retina; 2014 Dec; 34 Suppl 12():S1-S18. PubMed ID: 25489719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prediction Model for the Intraocular Pharmacokinetics of Intravitreally Injected Drugs Based on Molecular Physicochemical Properties.
    Kim HM; Park KH; Chung JY; Woo SJ
    Ophthalmic Res; 2020; 63(1):41-49. PubMed ID: 31112980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.